Posted by Michael Wonder on 28 Apr 2021
Rockwell Medical announces marketing approval of Triferic AVNU in Canada
27 March 2021 - Rockwell Medical today announced that Triferic AVNU (ferric pyrophosphate citrate injection) received a Notice of Compliance (marketing approval) from Health Canada for the replacement of iron to maintain haemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.
Rockwell Medical expects Triferic AVNU to become commercially available in Canada during 2022.
